Identification of Human Papillomavirus Type 16 L1 Surface Loops Required for Neutralization by Human Sera
- 15 May 2006
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 80 (10) , 4664-72
- https://doi.org/10.1128/jvi.80.10.4664-4672.2006
Abstract
The variable surface loops on human papillomavirus (HPV) virions required for type-specific neutralization by human sera remain poorly defined. To determine which loops are required for neutralization, a series of hybrid virus-like particles (VLPs) were used to adsorb neutralizing activity from HPV type 16 (HPV16)-reactive human sera before being tested in an HPV16 pseudovirion neutralization assay. The hybrid VLPs used were composed of L1 sequences of either HPV16 or HPV31, on which one or two regions were replaced with homologous sequences from the other type. The regions chosen for substitution were the five known loops that form surface epitopes recognized by monoclonal antibodies and two additional variable regions between residues 400 and 450. Pretreatment of human sera, previously found to react to HPV16 VLPs in enzyme-linked immunosorbent assays, with wild-type HPV16 VLPs and hybrid VLPs that retained the neutralizing epitopes reduced or eliminated the ability of sera to inhibit pseudovirus infection in vitro. Surprisingly, substitution of a single loop often ablated the ability of VLPs to adsorb neutralizing antibodies from human sera. However, for all sera tested, multiple surface loops were found to be important for neutralizing activity. Three regions, defined by loops DE, FG, and HI, were most frequently identified as being essential for binding by neutralizing antibodies. These observations are consistent with the existence of multiple neutralizing epitopes on the HPV virion surface.Keywords
This publication has 41 references indexed in Scilit:
- Humoral Immune Response Recognizes a Complex Set of Epitopes on Human Papillomavirus Type 6 L1 CapsomersJournal of Virology, 2005
- Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18Virology, 2004
- Identification of a Human Papillomavirus Type 16-Specific Epitope on the C-Terminal Arm of the Major Capsid Protein L1Journal of Virology, 2003
- Hybrid Papillomavirus L1 Molecules Assemble into Virus-like Particles That Reconstitute Conformational Epitopes and Induce Neutralizing Antibodies to Distinct HPV TypesVirology, 2001
- A Novel Human Papillomavirus Type 6 Neutralizing Domain Comprising Two Discrete Regions of the Major Capsid Protein L1Virology, 2001
- Comparison of Human Papillomavirus Types 16, 18, and 6 Capsid Antibody Responses Following Incident InfectionThe Journal of Infectious Diseases, 2000
- HPV11 Mutant Virus-like Particles Elicit Immune Responses That Neutralize Virus and Delineate a Novel Neutralizing DomainVirology, 2000
- The Natural History of Human Papillomavirus Type 16 Capsid Antibodies among a Cohort of University WomenThe Journal of Infectious Diseases, 1996
- Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.Proceedings of the National Academy of Sciences, 1995
- Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formationVaccine, 1995